Tiburio Therapeutics Inc. (Tiburio), a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and endocrine diseases, today announced the appointment of Nerissa Kreher, MD, to the newly created position of Chief Medical Officer. Dr. Kreher brings 13 years of experience in medical affairs and clinical development from leading biotechnology companies, most recently serving as Chief Medical Officer at AVROBIO, a gene therapy company. There, she led all clinical development and clinical operations for multiple global rare disease programs, including programs for Fabry and Gaucher disease, among others.
Cydan today announced the launch of Tiburio Therapeutics Inc. (Tiburio), a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases. Tiburio will advance two compounds licensed from Ipsen for the treatment of non-functioning pituitary adenoma (NFPA) (TBR-760) and for additional rare endocrine diseases (TBR-065). As part of the launch, Tiburio raised a $31M Series A financing that will fund the company’s lead compound, TBR-760, through human proof-of-concept for the treatment of NFPA and further clinical assessment of TBR-065 as a treatment for rare endocrine diseases. In conjunction with the Tiburio financing, Abraham N. Ceesay has been appointed chief executive officer of the company.